Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) Debt to Equity (2016 - 2025)

Integra Lifesciences Holdings' Debt to Equity history spans 17 years, with the latest figure at $1.66 for Q4 2025.

  • For Q4 2025, Debt to Equity rose 54.2% year-over-year to $1.66; the TTM value through Dec 2025 reached $1.66, up 54.2%, while the annual FY2025 figure was $1.66, 54.2% up from the prior year.
  • Debt to Equity for Q4 2025 was $1.66 at Integra Lifesciences Holdings, down from $1.68 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.68 in Q3 2025 and bottomed at $0.43 in Q4 2022.
  • The 5-year median for Debt to Equity is $0.55 (2023), against an average of $0.78.
  • The largest annual shift saw Debt to Equity dropped 26.99% in 2021 before it skyrocketed 112.64% in 2025.
  • A 5-year view of Debt to Equity shows it stood at $0.52 in 2021, then decreased by 17.15% to $0.43 in 2022, then grew by 23.78% to $0.53 in 2023, then soared by 103.18% to $1.07 in 2024, then skyrocketed by 54.2% to $1.66 in 2025.
  • Per Business Quant, the three most recent readings for IART's Debt to Equity are $1.66 (Q4 2025), $1.68 (Q3 2025), and $1.63 (Q2 2025).